Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Actavis plc and Valeant Pharmaceuticals International Inc announce FDA approval for Metronidazole 1.3pct


Tuesday, 25 Mar 2014 05:00pm EDT 

Actavis plc and Valeant Pharmaceuticals International, Inc:Says U.S. Food and Drug Administration (FDA) has approved New Drug Application (NDA) for Metronidazole 1.3pct Vaginal Gel.Actavis will acquire the rights to Metronidazole 1.3pct for up to $57 mln in up front payments, milestone payments and certain guaranteed royalty payments during first three years of commercialization depending on market conditions.